DOCSLIB.ORG

Jules Stein Eye Institute Itute

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Jules Stein Eye Institute Itute Annual Report 2007–2008 Annual Report 2007–2008 Jules Stein Eye Institute Jules Stein Eye Institute David Geffen School of Medicine at UCLA University of California, Los Angeles Jules Stein Eye Institute 2007 – 2008 Annual Report 2007–2008 Jules Stein Eye Institute David Geffen School of Medicine at UCLA University of California, Los Angeles ii FacultyAppendices | Endowed Professorships, Fellowships, and Other Funds Jules Stein Eye Institute Annual Report 2007–2008 DIRECTOR Bartly J. Mondino, MD FACULTY ADVISOR Debora B. Farber, PhD, DPhhc MANAGING EDITOR Gloria P. Jurisic EDITORS Irene Y. Chen Tina-Marie Gauthier PHOTOGRAPHY J. Charles Martin DESIGN This report covers the period July 1, 2007, through June 30, 2008. Ikkanda Design Group Requests for additional copies of the publication Jules Stein Eye Institute PRINTING Annual Report 2007–2008 Marina Graphic Center may be sent to: ©2008, by the Regents of the University of California. Office of the Managing Editor All rights reserved. Jules Stein Eye Institute 100 Stein Plaza, UCLA Box 957000 Los Angeles, California 90095–7000 Printed on recycled paper using soy base inks Phone: (310) 206-7178 For more information on the Institute, see our website: www.jsei.org The emblem of the Jules Stein Eye Institute is adapted from the schematic eye used by Sir Isaac Newton in his classic treatise on human vision—“Opticks”—published in 1704. The horizontal lines extending from the surface of the eye represent Newton’s concept of the major colors that are in the spectrum of light. Appendices | Endowed Professorships, Fellowships, and Other Funds iii Contents JULES STEIN v DORIS STEIN v BOARD OF TRUSTEES vi EXECUTIVE COMMITTEE vii FACILITIES viii HIGHLIGHTS 1 Honors 3 Research 6 Education 7 Philanthropy 10 Thank You 12 Community Outreach 13 FACULTY 15 PROGRAMS 63 Patient Care Services 64 Research and Treatment Centers 65 Clinical Laboratories 72 Training Programs 74 APPENDICES 81 Volunteer and Consulting Faculty 82 Residents and Fellows 84 Endowed Professorships, Fellowships, and Other Funds 86 Educational Offerings 90 Research Contracts and Grants 93 Clinical Research Studies 106 Publications of the Full-Time Faculty 111 Giving Opportunities 124 iv Faculty The legacy of Dr. and Mrs. Jules Stein arises from their role in the 20th century as visionaries. Through brilliance and beneficence, they created a multitude of programs aimed specifically at one goal—preserving and restoring eyesight. They approached this task dauntlessly, integrating the worlds of business, medicine, and philanthropy in such a way as to enhance each and leave in trust the promise of limitless accomplishment in the advancement of eye research and treatment. The Jules Stein Eye Institute was established as a result of their philanthropy. Jules and Doris Stein v Jules Stein Institute was founded as a multidisciplinary center for vision science. Since its establishment, the Institute has become internationally identified as the focus for coordinated programs of research in the sciences related to vision, Jules Stein is the foremost benefactor ophthalmic education, and the care of patients with eye in the world history of vision science disease. Jules Stein died in 1981, leaving a legacy of hope to and blindness prevention. He the world. Through his accomplishments and philanthropy, combined his love for music and he created ever replenishing resources for eye research and medicine with a unique talent for the means to preserve and restore sight for future generations. analysis and organization to produce a lifetime of celebrated achievements as musician, physician, business leader, and humanitarian. Doris Stein Born in South Bend, Indiana, in 1896, Jules Stein received a PhB from the University of Chicago at age 18 followed by Doris Stein’s purposeful, yet richly a MD degree from Rush Medical College. After completing varied life earned the respect and postgraduate studies at the University of Vienna and Chicago’s affection of the many people who Cook County Hospital, he began medical practice and was benefited from her humanitarianism. certified by the American Board of Ophthalmology. Inspiring partner of her husband for more than half a century, Doris Stein A musician from an early age, he financed his education by shared with him the accomplishments of his philanthropic playing in and leading his own band. As his reputation endeavors and guided his interests in ophthalmology, increased, he began booking other musicians for professional beginning with a visit to the New York Lighthouse for the engagements, and in 1924 founded Music Corporation of Blind in the late 1950s. Deeply moved, Doris Stein urged her America (MCA). Shortly thereafter, he gave up the practice husband to “do something!” From that passionate beginning of medicine to concentrate on this enterprise. Within 10 came a broad base of programs that catalyzed eye research. years, MCA represented most of the great name bands and corporate activities began to extend to representation of film Doris Stein was a major force in this vision renaissance. stars, directors, writers, and musical artists. MCA entered the She served as an officer and director of Research to Prevent promising new field of television at its inception, eventually Blindness, personally leading the appeal to establish more acquiring the Universal City property, Universal Pictures, resources for investigations into eye diseases. She suggested and other enterprises to become pre-eminent in the that Jules Stein assume the principal role in the creation entertainment industry. of an eye institute at UCLA, and her unflagging enthusiasm nurtured the Institute’s development as a unique provider Throughout his phenomenally successful career, Jules Stein of every facet of vision research and patient care. Serving as maintained a strong interest and emotional investment in Trustee, she focused special attention on Institute initiatives medicine, particularly his own field of ophthalmology. In the to combat blindness throughout the world. She devoted her late 1950s, urged by his wife, Doris, he chose to direct his last days, until her death in 1984, to the development of an considerable talents to blindness prevention. The result expansion and companion building for eye research. In 1989, was a concert of ideas and achievements that encompassed dedication ceremonies were held for the Doris Stein Eye philanthropy, government, and academic medicine. Research Center. By his efforts, Research to Prevent Blindness was created, now With grace, vision, and meaningful action, Doris Stein recognized as the world’s leading voluntary organization in enhanced the lives of all privileged to know her, stimulated a support of studies of the eye and its diseases. Jules Stein was cascade of progress in eye research, co-founded the Institute largely responsible for the passage of legislation to establish with its boundless scientific potential, and extended the the National Eye Institute as a separate entity in the National miracle of sight to untold numbers of people. Institutes of Health. Under his leadership, the Jules Stein Eye vi FacultyBoard of Trustees BOARD OF TRUSTEES The Jules Stein Eye Institute Board of Trustees was established for the Institute, adoption of measures to facilitate recruitment in 1977 to ensure the Institute’s orderly growth and of the world’s finest vision scientists, allocation of funds for development. The Board meets regularly during the year, with the purchase of vision research equipment, and each Trustee providing his/her unique counsel. Collectively, recommendations for facilities expansion programs. their invaluable contributions have included fiscal planning Current Members Bartly J. Mondino, MD Nelson C. Rising, Esq. Director Chairman and CEO Jules Stein Eye Institute Rising Realty Partners, LLC 1994–present 2004–present Ronald L. Olson, Esq. George A. Smith, Esq. Partner Consultant Munger, Tolles, and Olson 1992–present 1995–present Gerald H. Oppenheimer Katrina Vanden Heuvel President Publisher and Editor Gerald Oppenheimer The Nation Magazine Family Foundation 1984–present President Systems Design Associates 1992–present Andrea L. Rich, PhD Casey Wasserman Retired President, Chief Executive Chief Executive Officer Officer and Director The Wasserman Foundation Los Angeles County Museum of Art 1998–present Executive Vice Chancellor Emerita UCLA 2007–present Executive Committee vii EXECUTIVE COMMITTEE Director, Jules Stein Eye Institute Vice-Chairmen, UCLA Department of Ophthalmology Chairman, UCLA Department of Ophthalmology Sherwin J. Isenberg, MD Bartly J. Mondino, MD Arthur L. Rosenbaum, MD Associate Directors, Jules Stein Eye Institute Chief Administrative Officer, Jules Stein Eye Institute Wayne L. Hubbell, PhD Jonathan D. Smith Gabriel H. Travis, MD Jules Stein Eye Institute Executive Committee: (sitting from left to right) Drs. Gabriel Travis, Arthur Rosenbaum, Sherwin Isenberg, and Bartly Mondino; (standing from left to right) Mr. Jonathan Smith and Dr. Wayne Hubbell. viii FacultyFacilities FACILITIES The facilities of the Jules Stein Eye Institute comprise two free- standing structures of architectural note. The five-story Jules Stein Eye Institute building, occupying 110,000 square feet, is of neo-classical design. It is the original facility, constructed in 1966. An expansion and companion building, the Doris Stein Eye Research Center, followed in 1989. It is a four-story, red granite structure, occupying 67,000 square feet, and connecting with the Jules Stein
Load more

Recommended publications
  • Genetic Testing for Non-Cancerous Inheritable Diseases
    Genetic Testing for Non-Cancerous Inheritable Diseases Policy Number: Original Effective Date: MM.02.009 03/01/2010 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 12/30/2016 Section: Medicine Place(s) of Service: Outpatient I. Description A genetic test is the analysis of human DNA, RNA, chromosomes, proteins, or certain metabolites in order to detect alterations related to an inheritable disorder. This can be accomplished by directly examining the DNA or RNA that makes up a gene (direct testing), looking at markers co-inherited with a disease-causing gene (linkage testing), assaying certain metabolites (biochemical testing), or examining the chromosomes (cytogenetic testing). Genetic tests are conducted for a number of purposes, including predicting disease risk, newborn screening, determining clinical management, identifying carriers, and establishing prenatal or clinical diagnoses or prognoses in individuals, families, or populations. Expanded Carrier Screening The American College of Medical Genetics (ACMG ) defines expanded panels as those that use next- generation sequencing to screen for mutations in many genes, as opposed to gene-by-gene screening (e.g., ethnic-specific screening or panethnic testing for cystic fibrosis). An ACMG position statement states that although commercial laboratories offer expanded carrier screening panels, there has been no professional guidance as to which disease genes and mutations to include. This policy does not address oncology-related genetic testing or pre-implantation genetic diagnosis (PGD). II. Criteria/Guidelines Note: For familial assessments, unless otherwise specified, family will be considered: first-, second- and third- degree relatives on the same side of the family. The maternal and paternal sides should be considered independently.
    [Show full text]
  • 2017 Report to the Community
    HERE AND Report to the Community | 2017 NOW LEADERSHIP CONTENTS MESSAGE Leadership Message 1 crucial neighborhood caregivers. When added Patient Care 2 to our longstanding partnerships with local schools, homeless shelters and other community Research 16 organizations, we are doing more than ever to It all began with the spark of an idea. In aid all those who need quality healthcare. Community 1902, a growing Los Angeles community was Outreach 30 struggling to get quality healthcare, so a group Meanwhile, locally and throughout the nation, of civic leaders came together to create the consumers, payers and employers are asking for Education 38 the forerunner of Cedars-Sinai, the 12-bed better coordination of care to help people get Kaspare Cohn Hospital in the Angelino Heights and stay healthy, ensure that patients always The Campaign neighborhood east of downtown Los Angeles. get the right amount of care and help keep for Cedars-Sinai 44 healthcare affordable for all. You will see many Much has changed in medicine and healthcare examples in this report of how Cedars-Sinai is The Numbers 52 over the past 115 years, yet Cedars-Sinai is still pioneering new ways to provide healthcare that driven every day by the same fundamental is not only of the highest quality, but also has Where We Are 54 question: “What does the community need?” the value and efficiency that the public wants. Leadership 2016 56 One of our top priorities today is to respond Throughout these pages, you also will see to the demand for more accessible, convenient how our pioneering biomedical research and healthcare.
    [Show full text]
  • Genes in Eyecare Geneseyedoc 3 W.M
    Genes in Eyecare geneseyedoc 3 W.M. Lyle and T.D. Williams 15 Mar 04 This information has been gathered from several sources; however, the principal source is V. A. McKusick’s Mendelian Inheritance in Man on CD-ROM. Baltimore, Johns Hopkins University Press, 1998. Other sources include McKusick’s, Mendelian Inheritance in Man. Catalogs of Human Genes and Genetic Disorders. Baltimore. Johns Hopkins University Press 1998 (12th edition). http://www.ncbi.nlm.nih.gov/Omim See also S.P.Daiger, L.S. Sullivan, and B.J.F. Rossiter Ret Net http://www.sph.uth.tmc.edu/Retnet disease.htm/. Also E.I. Traboulsi’s, Genetic Diseases of the Eye, New York, Oxford University Press, 1998. And Genetics in Primary Eyecare and Clinical Medicine by M.R. Seashore and R.S.Wappner, Appleton and Lange 1996. M. Ridley’s book Genome published in 2000 by Perennial provides additional information. Ridley estimates that we have 60,000 to 80,000 genes. See also R.M. Henig’s book The Monk in the Garden: The Lost and Found Genius of Gregor Mendel, published by Houghton Mifflin in 2001 which tells about the Father of Genetics. The 3rd edition of F. H. Roy’s book Ocular Syndromes and Systemic Diseases published by Lippincott Williams & Wilkins in 2002 facilitates differential diagnosis. Additional information is provided in D. Pavan-Langston’s Manual of Ocular Diagnosis and Therapy (5th edition) published by Lippincott Williams & Wilkins in 2002. M.A. Foote wrote Basic Human Genetics for Medical Writers in the AMWA Journal 2002;17:7-17. A compilation such as this might suggest that one gene = one disease.
    [Show full text]
  • Preconception Carrier Screening
    Focusing on Personalised Medicine PRECONCEPTION CARRIER SCREENING Preconception carrier screening is an important tool for prospective parents to help them determine their risk of having a child affected with a heritable disease. In many cases, parents aren’t aware they are carriers and have no family history due to the rarity of some diseases in the general population. What is covered by the screening? Our Inherited Disease Panel tests over 300 genes associated with more than 700 unique commonly inherited diseases, including common forms of inherited deafness, blindness, heart disease, Parkinson’s disease, immunodeficiency, and various ataxias, anaemias, and treatable metabolic syndromes. The assay has been developed in conjunction with clinical molecular geneticists, and includeds genes listed in the NIH Genetic Test Registry. For a full list of genes and disorders covered, please see the reverse of this brochure. Why have Preconception Carrier Screening? Carrier screening prior to pregnancy enables couples to learn about their reproductive risk and consider a complete range of reproductive options, including whether or not to become pregnant, whether to use advanced reproductive technologies, such as preimplantation genetic diagnosis, or use donor gametes. Screening also allows couples to consider prenatal diagnosis and pregnancy management options in the event of an affected fetus. Whilst individually each disease tested is rare, around 25% of people will carry at least one abnormal mutation. These disorders are usually autosomal recessive, which means that a child must inherit a defective gene from each parent to have the disease. For autosomal recessive conditions, if a person is a carrier of the disease, they have one defective copy of the gene and one normal copy and typically don’t have any symptoms of the disease.
    [Show full text]
  • Diseases of the Digestive System (KOO-K93)
    CHAPTER XI Diseases of the digestive system (KOO-K93) Diseases of oral cavity, salivary glands and jaws (KOO-K14) lijell Diseases of pulp and periapical tissues 1m Dentofacial anomalies [including malocclusion] Excludes: hemifacial atrophy or hypertrophy (Q67.4) K07 .0 Major anomalies of jaw size Hyperplasia, hypoplasia: • mandibular • maxillary Macrognathism (mandibular)(maxillary) Micrognathism (mandibular)( maxillary) Excludes: acromegaly (E22.0) Robin's syndrome (087.07) K07 .1 Anomalies of jaw-cranial base relationship Asymmetry of jaw Prognathism (mandibular)( maxillary) Retrognathism (mandibular)(maxillary) K07.2 Anomalies of dental arch relationship Cross bite (anterior)(posterior) Dis to-occlusion Mesio-occlusion Midline deviation of dental arch Openbite (anterior )(posterior) Overbite (excessive): • deep • horizontal • vertical Overjet Posterior lingual occlusion of mandibular teeth 289 ICO-N A K07.3 Anomalies of tooth position Crowding Diastema Displacement of tooth or teeth Rotation Spacing, abnormal Transposition Impacted or embedded teeth with abnormal position of such teeth or adjacent teeth K07.4 Malocclusion, unspecified K07.5 Dentofacial functional abnormalities Abnormal jaw closure Malocclusion due to: • abnormal swallowing • mouth breathing • tongue, lip or finger habits K07.6 Temporomandibular joint disorders Costen's complex or syndrome Derangement of temporomandibular joint Snapping jaw Temporomandibular joint-pain-dysfunction syndrome Excludes: current temporomandibular joint: • dislocation (S03.0) • strain (S03.4) K07.8 Other dentofacial anomalies K07.9 Dentofacial anomaly, unspecified 1m Stomatitis and related lesions K12.0 Recurrent oral aphthae Aphthous stomatitis (major)(minor) Bednar's aphthae Periadenitis mucosa necrotica recurrens Recurrent aphthous ulcer Stomatitis herpetiformis 290 DISEASES OF THE DIGESTIVE SYSTEM Diseases of oesophagus, stomach and duodenum (K20-K31) Ill Oesophagitis Abscess of oesophagus Oesophagitis: • NOS • chemical • peptic Use additional external cause code (Chapter XX), if desired, to identify cause.
    [Show full text]
  • Oculocutaneous Albinism, a Family Matter Summer Moon, DO,* Katherine Braunlich, DO,** Howard Lipkin, DO,*** Annette Lacasse, DO***
    Oculocutaneous Albinism, A Family Matter Summer Moon, DO,* Katherine Braunlich, DO,** Howard Lipkin, DO,*** Annette LaCasse, DO*** *Dermatology Resident, 3rd year, Botsford Hospital Dermatology Residency Program, Farmington Hills, MI **Traditional Rotating Intern, Largo Medical Center, Largo, FL ***Program Director, Botsford Hospital Dermatology Residency Program, Farmington Hills, MI Disclosures: None Correspondence: Katherine Braunlich, DO; [email protected] Abstract Oculocutaneous albinism (OCA) is a group of autosomal-recessive conditions characterized by mutations in melanin biosynthesis with resultant absence or reduction of melanin in the melanocytes. Herein, we present a rare case of two Caucasian sisters diagnosed with oculocutaneous albinism type 1 (OCA1). On physical exam, the sisters had nominal cutaneous evidence of OCA. This case highlights the difficulty of diagnosing oculocutaneous albinism in Caucasians. Additionally, we emphasize the uncommon underlying genetic mutations observed in individuals with oculocutaneous albinism. 2,5 Introduction people has one of the four types of albinism. of exon 4. Additionally, patient A was found to Oculocutaneous albinism (OCA) is a group of We present a rare case of sisters diagnosed with possess the c.21delC frameshift mutation in the autosomal-recessive conditions characterized by oculocutaneous albinism type 1, emphasizing the C10orf11 gene. Patient B was found to possess the mutations in melanin biosynthesis with resultant uncommon genetic mutations we observed in these same heterozygous mutation and deletion in the two individuals. absence or reduction of melanin in the melanocytes. Figure 1 Melanin-poor, pigment-poor melanocytes phenotypically present as hypopigmentation of the Case Report 1,2 Two Caucasian sisters were referred to our hair, skin, and eyes. dermatology clinic after receiving a diagnosis of There are four genes responsible for the four principal oculocutaneous albinism type 1.
    [Show full text]
  • Albinism: Modern Molecular Diagnosis
    British Journal of Ophthalmology 1998;82:189–195 189 Br J Ophthalmol: first published as 10.1136/bjo.82.2.189 on 1 February 1998. Downloaded from PERSPECTIVE Albinism: modern molecular diagnosis Susan M Carden, Raymond E Boissy, Pamela J Schoettker, William V Good Albinism is no longer a clinical diagnosis. The past cytes and into which melanin is confined. In the skin, the classification of albinism was predicated on phenotypic melanosome is later transferred from the melanocyte to the expression, but now molecular biology has defined the surrounding keratinocytes. The melanosome precursor condition more accurately. With recent advances in arises from the smooth endoplasmic reticulum. Tyrosinase molecular research, it is possible to diagnose many of the and other enzymes regulating melanin synthesis are various albinism conditions on the basis of genetic produced in the rough endoplasmic reticulum, matured in causation. This article seeks to review the current state of the Golgi apparatus, and translocated to the melanosome knowledge of albinism and associated disorders of hypo- where melanin biosynthesis occurs. pigmentation. Tyrosinase is a copper containing, monophenol, mono- The term albinism (L albus, white) encompasses geneti- oxygenase enzyme that has long been known to have a cally determined diseases that involve a disorder of the critical role in melanogenesis.5 It catalyses three reactions melanin system. Each condition of albinism is due to a in the melanin pathway. The rate limiting step is the genetic mutation on a diVerent chromosome. The cutane- hydroxylation of tyrosine into dihydroxyphenylalanine ous hypopigmentation in albinism ranges from complete (DOPA) by tyrosinase, but tyrosinase does not act alone.
    [Show full text]
  • VENICE FAMILY CLINIC: Improving Capacity and Managing Patient Lead Times
    CASE STUDY, 4/2012 VENICE FAMILY CLINIC: Improving capacity and managing patient lead times PREPARED BY Professor Kumar Rajaram, UCLA Anderson School of Management Karen Conner, MD, UCLA David Geffen School of Medicine A case by the Johnson & Johnson/UCLA Health Care Executive Program and the UCLA Anderson School of Management Dr. Susan Fleishman, Medical Director at the Venice Family Clinic (VFC) returned to the clinic after her early morning meeting with CEO, Elizabeth Forer. It was a typically warm and sunny Southern California day as she approached the front door of the clinic. She walked past a line of six to eight people waiting to check in at security and then proceeded upstairs to the waiting room. Almost every seat was taken. The room was full of elderly people, homeless men and women, young mothers, babies, toddlers with runny noses, school-aged children watching TV and adult men and women dressed for work. Some clutched papers indicating they had been seen by either registration or a provider, but most were holding only their color-coded cards given to them as they passed through security. As she headed towards the patient rooms, she noticed two resident doctors holding charts and chatting about their upcoming ski trips, one attending physician talking to a medical assistant about lab work and another on the telephone impatiently waiting on hold. A quick walk by the patient rooms showed that despite the crowd in the waiting room, only about half of the rooms had patients in them. She knew that many of the patients seen by the clinic spent hours there each visit, and that most of that time was spent waiting.
    [Show full text]
  • Soonerstart Automatic Qualifying Syndromes and Conditions
    SoonerStart Automatic Qualifying Syndromes and Conditions - Appendix O Abetalipoproteinemia Acanthocytosis (see Abetalipoproteinemia) Accutane, Fetal Effects of (see Fetal Retinoid Syndrome) Acidemia, 2-Oxoglutaric Acidemia, Glutaric I Acidemia, Isovaleric Acidemia, Methylmalonic Acidemia, Propionic Aciduria, 3-Methylglutaconic Type II Aciduria, Argininosuccinic Acoustic-Cervico-Oculo Syndrome (see Cervico-Oculo-Acoustic Syndrome) Acrocephalopolysyndactyly Type II Acrocephalosyndactyly Type I Acrodysostosis Acrofacial Dysostosis, Nager Type Adams-Oliver Syndrome (see Limb and Scalp Defects, Adams-Oliver Type) Adrenoleukodystrophy, Neonatal (see Cerebro-Hepato-Renal Syndrome) Aglossia Congenita (see Hypoglossia-Hypodactylia) Aicardi Syndrome AIDS Infection (see Fetal Acquired Immune Deficiency Syndrome) Alaninuria (see Pyruvate Dehydrogenase Deficiency) Albers-Schonberg Disease (see Osteopetrosis, Malignant Recessive) Albinism, Ocular (includes Autosomal Recessive Type) Albinism, Oculocutaneous, Brown Type (Type IV) Albinism, Oculocutaneous, Tyrosinase Negative (Type IA) Albinism, Oculocutaneous, Tyrosinase Positive (Type II) Albinism, Oculocutaneous, Yellow Mutant (Type IB) Albinism-Black Locks-Deafness Albright Hereditary Osteodystrophy (see Parathyroid Hormone Resistance) Alexander Disease Alopecia - Mental Retardation Alpers Disease Alpha 1,4 - Glucosidase Deficiency (see Glycogenosis, Type IIA) Alpha-L-Fucosidase Deficiency (see Fucosidosis) Alport Syndrome (see Nephritis-Deafness, Hereditary Type) Amaurosis (see Blindness) Amaurosis
    [Show full text]
  • Hereditary Hearing Impairment with Cutaneous Abnormalities
    G C A T T A C G G C A T genes Review Hereditary Hearing Impairment with Cutaneous Abnormalities Tung-Lin Lee 1 , Pei-Hsuan Lin 2,3, Pei-Lung Chen 3,4,5,6 , Jin-Bon Hong 4,7,* and Chen-Chi Wu 2,3,5,8,* 1 Department of Medical Education, National Taiwan University Hospital, Taipei City 100, Taiwan; [email protected] 2 Department of Otolaryngology, National Taiwan University Hospital, Taipei 11556, Taiwan; [email protected] 3 Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei City 100, Taiwan; [email protected] 4 Graduate Institute of Medical Genomics and Proteomics, National Taiwan University College of Medicine, Taipei City 100, Taiwan 5 Department of Medical Genetics, National Taiwan University Hospital, Taipei 10041, Taiwan 6 Department of Internal Medicine, National Taiwan University Hospital, Taipei 10041, Taiwan 7 Department of Dermatology, National Taiwan University Hospital, Taipei City 100, Taiwan 8 Department of Medical Research, National Taiwan University Biomedical Park Hospital, Hsinchu City 300, Taiwan * Correspondence: [email protected] (J.-B.H.); [email protected] (C.-C.W.) Abstract: Syndromic hereditary hearing impairment (HHI) is a clinically and etiologically diverse condition that has a profound influence on affected individuals and their families. As cutaneous findings are more apparent than hearing-related symptoms to clinicians and, more importantly, to caregivers of affected infants and young individuals, establishing a correlation map of skin manifestations and their underlying genetic causes is key to early identification and diagnosis of syndromic HHI. In this article, we performed a comprehensive PubMed database search on syndromic HHI with cutaneous abnormalities, and reviewed a total of 260 relevant publications.
    [Show full text]
  • Analysis of Ocular Hypopigmentation in Rab38cht/Cht Mice
    ARTICLES Analysis of Ocular Hypopigmentation in Rab38cht/cht Mice Brian P. Brooks,1,2,3 Denise M. Larson,2,3 Chi-Chao Chan,1 Sten Kjellstrom,4 Richard S. Smith,5,6 Mary A. Crawford,1 Lynn Lamoreux,7 Marjan Huizing,3 Richard Hess,3 Xiaodong Jiao,1 J. Fielding Hejtmancik,1 Arvydas Maminishkis,1 Simon W. M. John,5,6 Ronald Bush,4 and William J. Pavan3 cht PURPOSE. To characterize the ocular phenotype resulting from and RPE thinning. The synergistic effects of the Rab38 and mutation of Rab38, a candidate gene for Hermansky-Pudlak Tyrp1b alleles suggest that TYRP1 is not the only target of syndrome. RAB38 trafficking. This mouse line provides a useful model for cht/cht METHODS. Chocolate mice (cht, Rab38 ) and control het- studying melanosome biology and its role in human ocular erozygous (Rab38cht/ϩ) and wild-type mice were examined diseases. (Invest Ophthalmol Vis Sci. 2007;48:3905–3913) clinically, histologically, ultrastructurally, and electrophysi- DOI:10.1167/iovs.06-1464 ologically. Mice homozygous for both the Rab38cht and the Tyrp1b alleles were similarly examined. he analysis of mice that exhibit defects in coat coloration cht/cht RESULTS. Rab38 mice showed variable peripheral iris trans- T(coat color mutants) has aided in the identification of 1 illumination defects at 2 months of age. Patches of RPE hypo- genes important in eye, skin, and hair pigmentation. Many of pigmentation were noted clinically in 57% of Rab38cht/cht eyes these genes are mutated in patients with pigmentary anoma- and 6% of Rab38cht/ϩ eyes. Rab38cht/cht mice exhibited thin- lies.
    [Show full text]
  • Genetic Testing Stories
    genetic alliance monograph series number 2 Genetic testinG stories nicole exe, ms heather Ferguson, ms, cgc alyson Krokosky samantha sawyer sharon F. terry, ma published by genetic alliance Genetic testinG stories nicole exe, ms heather Ferguson, ms, cgc alyson Krokosky samantha sawyer sharon F. terry, ma published by genetic alliance 1 Genetic Alliance is grateful to the individuals and families who so generously shared their stories. They offer us a model of openness that benefits all. Partial funding for this report was provided by the Genetics and Public Policy Center. The Center is supported at Johns Hopkins University by The Pew Charitable Trusts. Any opinions expressed in this report are those of the author(s) and do not necessarily reflect the views of The Pew Chari- table Trusts or the Genetics and Public Policy Center. This report may not be reproduced or distributed in whole or in part without the permission of the Genetics and Public Policy Center. Funding for this work was also provided by the Health Resources and Services Administration, Maternal Child Health Bureau, Genetics Services Branch, cooperative agreement # 1 U33MC07945-01-00, and Genetic Alliance. 4301 connecticut ave., nW, suite 404 Washington, dc 20008 t: 202.966.5557 F: 202.966.8553 www.geneticalliance.org 2 Table of Contents PREFACE 4 HYPOKALEMIC PERIODIC PARALYSIS Adult 26 CARRIER TESTING 5 HYPOSPADIAS/CHROMOSOMAL DEFECTS Child 27 22Q11.2 DELETION SYNDROME KLINEFELTER SYNDROME Adult 27 Adult/Newborn 5 MEDIUM CHAIN ACYL COA DEHYDROGENASE ADRENOLEUKODYSTROPHY
    [Show full text]